June 2026 in “Pathology & Oncology Research” In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.
September 2022 in “Concilium” This study found that scalp cooling effectively prevented chemotherapy-induced alopecia in patients, with a higher success rate observed in those who did not receive anthracyclines, although some experienced scalp pain and other mild adverse effects.
August 2026 in “PLoS ONE” This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.
5 citations
,
January 2024 in “BMC Cancer” In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.
June 2025 in “World Journal of Medical Oncology” In this study, researchers explored the use of new biobased compounds and gels as potential treatments for skin cancer, finding that these biological materials may be significant in limiting and eliminating skin tumors alone or when combined with other methods.
